2024    2023    2022    2021    2020    2019    2018    2017    2016   

2022

Articles

31 - 

Axicabtagene Ciloleucel As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Primary Analysis of Alycante, a Phase 2 Lysa Study

Roch Houot, Emmanuel Bachy, Guillaume Cartron, François-Xavier Gros, Franck Morschhauser, Lucie Obéric, Thomas Gastinne, Pierre Feugier, Rémy Duléry, Catherine Thieblemont et al.

Blood, 2022, 140 (Supplement 1),

DOI : https://doi.org/10.1182/blood-2022-156626

 

32 - 

Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma

Roch Houot, Viola Poeschel, Bettina Altmann, Stephanie Angel, Lorenz Thurner, Thomas Illmer, Marc Andre, Martin Dreyling, Herve Maisonneuve, Hervé Tilly et al.

HemaSphere, 2022, 6 (2),

DOI : https://doi.org/10.1097/HS9.0000000000000672

Pubmed : 35028526

 

33 - 

An International Society for Cell and Gene Therapy Mesenchymal Stromal Cells Committee editorial on overcoming limitations in clinical trials of mesenchymal stromal cell therapy for coronavirus disease-19: time for a global registry

Daniel J Weiss, Anthony Filiano, Jacques Galipeau, Maroun Khoury, Mauro Krampera, Manoj Lalu, Katarina Le Blanc, Jan Nolta, Donald G Phinney, Patricia R M Rocco et al.

Cytotherapy, 2022, 24 (11), pp.1071-1073.

DOI : https://doi.org/10.1016/j.jcyt.2022.07.010

Pubmed : 36028438

 

34 - 

RNA-based immunoglobulin repertoire sequencing is a new tool for the management of monoclonal gammopathy of renal (kidney) significance

Vincent Javaugue, Virginie Pascal, Sébastien Bender, Sarah Nasraddine, Mathilde Dargelos, Mehdi Alizadeh, Alexis Saintamand, Matthieu Filloux, Paco Derouault, Sabrina Bouyer et al.

Kidney International, 2022, 101 (2), pp.331-337.

DOI : https://doi.org/10.1016/j.kint.2021.10.017

Pubmed : 34767830

 

35 - 

RNA exosome drives early B cell development via noncoding RNA processing mechanisms

Brice Laffleur, Carolina R. Batista, W Zhang, J Lim, Biao Yang, Delphine Rossille, L Wu, J.erson Estrella, Gerson Rothschild, Evangelos Pefanis et al.

Science Immunology, 2022, 7 (72), pp.eabn2738.

DOI : https://doi.org/10.1126/sciimmunol.abn2738

Pubmed : 35658015

 

36 - 

Histological Subtypes Drive Distinct Prognostic Immune Signatures in Classical Hodgkin Lymphoma

Claire Lamaison, Juliette Ferrant, Pauline Gravelle, Alexandra Traverse Glehen, Hervé Ghesquières, Marie Tosolini, Cedric Rossi, Loic Ysebaert, Pierre Brousset, Camille Laurent et al.

Cancers, 2022, 14 (19), pp.4893.

DOI : https://doi.org/10.3390/cancers14194893

Pubmed : 36230815

 

37 - 

Thrombosis with Non-Proliferative Complete Blood Count Indicative of Underlying Myeloproliferative Neoplasm, Sythrom, a Study on Behalf of the FIM Group

Yannick Le Bris, Jean Galtier, Dina Naguib, Mathieu Wemeau, Jean Claude Chomel, Laurence Legros, Yan Beauverd, Lise Willems, Guillaume Denis, Françoise Boyer Perrard et al.

Thrombosis with Non-Proliferative Complete Blood Count Indicative of Underlying Myeloproliferative Neoplasm, Sythrom, a Study on Behalf of the FIM Group. Blood, 2022, 140 (Supplement 1), pp.9668-9669.

DOI : https://doi.org/10.1182/blood-2022-159928

 

38 - 

COPP-MS: COrticosteroids during the Post-Partum in relapsing Multiple Sclerosis patients

Soizic Leguy, Mathilde Lefort, Lucile Lescot, Audrey Michaud, Sandra Vukusic, Emmanuelle Le Page, Gilles Edan, Anne Kerbrat, Christine Lebrun-Frenay, Jérôme de Sèze et al.

Journal of Neurology, 2022, 269 (269), pp.5571-5581.

DOI : https://doi.org/10.1007/s00415-022-11215-7

Pubmed : 35737108

 

39 - 

Disease-specific outcomes after chimeric antigen receptor T-cell therapy

Jean Lemoine, Samuel Vic, Roch Houot

European Journal of Cancer, 2022, 160, pp.235-242.

DOI : https://doi.org/10.1016/j.ejca.2021.10.022

Pubmed : 34865943

 

40 - 

Nouvelle AMM: le brexucabtagene autoleucel pour les leucémies aiguës lymphoblastiques B de l’adulte en rechute ou réfractaires New European approval: Brexucabtagene autoleucel in adult relapsed/refractory acute lymphoblastic leukemia

Jean Lemoine, Tony Marchand

Nouvelle AMM: le brexucabtagene autoleucel pour les leucémies aiguës lymphoblastiques B de l’adulte en rechute ou réfractaires. Bulletin du Cancer, 2022, 109 (12), pp.1232-1233.

DOI : https://doi.org/10.1016/j.bulcan.2022.09.006

Pubmed : 36270817